What is Phi Life Sciences?
Phi Life Sciences operates as a molecular diagnostic and laboratory services firm headquartered in Charleston, South Carolina. The company's core business revolves around providing comprehensive clinical diagnostic services, with a particular emphasis on COVID-19 testing. Their service portfolio extends to encompass testing for infectious diseases, advanced cancer genomics, personalized medication management, and a suite of additional laboratory offerings. These include genetic counseling and support for clinical trial services, all aimed at delivering precision medicine solutions to healthcare providers and patients. Phi Life Sciences is also recognized as a registered point-of-care provider for rapid antigen testing, highlighting its role in public health infrastructure.
How much funding has Phi Life Sciences raised?
Phi Life Sciences has raised a total of $317K across 2 funding rounds:
Debt
$150K
Debt
$167K
Debt (2020): $150K with participation from PPP
Debt (2021): $167K led by PPP
What's next for Phi Life Sciences?
The substantial backing, characterized as a large-scale late-stage funding event, positions Phi Life Sciences for significant growth and strategic scaling. This capital infusion is expected to fuel advancements in their precision medicine initiatives, potentially expanding their diagnostic capabilities and laboratory service reach. The company is likely to focus on enhancing its technological infrastructure, broadening its market presence, and potentially exploring new therapeutic areas or diagnostic applications. This strategic financing indicates strong investor confidence in Phi Life Sciences' business model and its capacity to innovate within the competitive healthcare and diagnostics landscape.
See full Phi Life Sciences company page
